Adaptive Platform Treatment Trial for Outpatients with COVID-19 - ACTIV-2
Study Overview
The ACTIV-2 Study is testing an investigational medicine to see if they are safe and can help adults with COVID-19 get better.
The type of investigational medicine you might receive in the study is a monoclonal antibody. Antibodies are naturally made by your body to help fight disease. Monoclonal antibodies are made in the laboratory and help your body attack invaders, such as viruses, to keep them from entering your cells.
We also want to see if this study drug is safe, can stop the disease process and prevent hospitalization.
If you decide to join, you would be given information about the medicines currently being tested.
Study Description
The study lasts about 6 months. You will have in-person visits to check on the status of your health. Most of these visits will happen during the first month of the study. You will also have phone calls or video chats from your home with a researcher.
Additional Information:
To find out more information please visit:
https://www.riseabovecovid.org/en/
- Study Identifier: 843864
